Circulating Tumor Cell Articles & Analysis
14 news found
As part of the collaboration, Tethis has placed one of its automated See.d instruments in the Cristofanilli lab, and the lab will use the instrument to isolate plasma and prepare cytology slides containing cells, including circulating tumor cells, from the blood. The Cristofanilli lab will analyze the isolated plasma samples for ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at ...
(USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor ...
Rarecells leverages its proprietary ISET® Circulating Tumor Cells (CTC) platform, combined with cutting-edge downstream analyses, to generate a novel and powerful approach to detect evidence of a tumor from a blood sample. ...
This research opens a new interesting way to look at the very rare cancer cells in the patient bloodstream. Rarecells Diagnostics (France), a leading liquid biopsy company, is pleased to announce that the University Medical Center of Groningen, The Netherlands, has published research comparing the performance of the ISET technology to the reference antibody-based system in ...
” Rarecells Inc. is a leading company in the development of innovative non-invasive tests for very Early Cancer Diagnosis based on a proprietary hypersensitive AI-based Circulating Tumor Cells (CTCs) and CTC-DNA detection. Founded in 2012, the firm is headquartered in New York and maintains offices and laboratories in New York and Paris. ...
Singaporean medical technology specialist X-ZELL has appointed Sebastian Grote as Managing Director, effective from 1 March 2022. Grote previously served as Head of Marketing & Strategy at X-ZELL and has been with the company since 2017, when it first came out of stealth mode to raise a two-part, USD 5.6m seed round. Since then, he initiated a series of global brand-building campaigns that ...
New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan from Mahidol University’s ...
X-ZELL’s widely recognised high-gradient magnetic Cell Separator (hMX™) is now available to researchers worldwide. Previously exclusive to X-ZELL, the patented system is part of the company’s single-cell diagnostics platform, which is capable of isolating and visualising individual atypical cells from a small 10mL blood sample. According to X-ZELL’s Head of Engineering ...
Award-winning Singaporean start-up, X-ZELL, has announced the formation of a new, interdisciplinary Imaging Technology division. The announcement comes on the back of a new collaboration agreement with Finnish Artificial Intelligence (AI) specialist, Aiforia Technologies, and is part of the ongoing digitisation of X-ZELL’s patented rare cell detection technology. X-ZELL’s modular ...
The company’s proprietary nanocoated slides combined with the automated pre-analytical instrument allow to identify and characterize rare cells in blood, like circulating tumor cells, with unprecedented sensitivity, also in early stage ...
Rarecells Inc., a leading Liquid Biopsy company is pleased to announce the development of an innovative and accurate targeted digital single-cell Next-Generation Sequencing (scNGS) for single-nucleotide variant (SNV) method to detect mutant genes of pancreatic ductal adenocarcinoma (PDAC) circulating tumor cells (CTC) enriched by ...
Study Published in British Journal of Cancer Shows High Sensitivity and Specificity of Tethis’ Liquid Biopsy Platform in Early Stage Breast Cancer and the Identification of Circulating Tumor Cells Clusters for the First Time in Non-Metastatic Patients Tethis S.p.A announced the publication of a pilot study in early breast cancer showing ...
Aceto is a world-renowned leader in circulating tumor cell research, and his work on CTC clusters has been published in the highest ranked scientific journals such as Nature and Cell. ...